Syne1 Deficiency
Summary
Clinical characteristics.
SYNE1 deficiency comprises a phenotypic spectrum that ranges from autosomal recessive cerebellar ataxia at the mild end to arthrogryposis multiplex congenita (AMC) at the severe end. SYNE1-deficient cerebellar ataxia, the most commonly recognized manifestation of SYNE1 deficiency to date, is a slowly progressive disorder typically beginning in adulthood (age range 6-45 years). While some individuals have a pure cerebellar syndrome (i.e., cerebellar ataxia, dysarthria, dysmetria, abnormalities in ocular saccades and smooth pursuit), many also have upper motor neuron dysfunction (spasticity, hyperreflexia, Babinski sign) and/or lower motor neuron dysfunction (amyotrophy, reduced reflexes, fasciculations). Most patients develop features of the cerebellar cognitive and affective syndrome (i.e., significant deficits in attention, executive functioning, verbal working memory, and visuospatial/visuoconstructional skills). The two less common phenotypes are SYNE1-deficient childhood-onset multisystem disease (ataxia, upper and lower motor neuron dysfunction, muscle weakness and wasting, intellectual disability) and SYNE1-deficient arthrogryposis multiplex congenita (decreased fetal movements and severe neonatal hypotonia associated with multiple congenital joint contractures including clubfoot).
Diagnosis/testing.
The diagnosis of SYNE1 deficiency is established in a proband with suggestive findings and biallelic SYNE1 pathogenic variants identified by molecular genetic testing.
Management.
Treatment of manifestations: There is no specific treatment for SYNE1 deficiency. The goals of treatment are to maximize function and reduce complications. Each patient should be managed by a multidisciplinary team of relevant specialists including neurologists, occupational therapists, physical therapists, physiatrists, orthopedists, nutritionists, speech therapists, respiratory therapists, and psychologists depending on the clinical manifestations.
Surveillance: Annual (or more often as needed) neurologic examination; assessment of mobility and self-help skills (as they relate to ataxia, spasticity, weakness), dysarthria, dysphagia, cognition, and psychiatric manifestations.
Genetic counseling.
SYNE1 deficiency is inherited in an autosomal recessive manner. The parents of an affected individual are obligate heterozygotes (i.e., carriers of one SYNE1 pathogenic variant). At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the SYNE1 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal diagnosis for a pregnancy at increased risk, and preimplantation genetic testing are possible.
Diagnosis
SYNE1 deficiency comprises a phenotypic spectrum that ranges from autosomal recessive cerebellar ataxia to arthrogryposis multiplex congenita (AMC).
Suggestive Findings
SYNE1 deficiency should be suspected in individuals with a combination of the following clinical features and/or clinical syndrome based on age of onset.
Clinical features
- Cerebellar ataxia
- Progressive ataxia of gait
- Clumsiness of hands
- Dysmetria
- Dysarthria
- Abnormalities in ocular saccades and smooth pursuit
- Upper and/or lower motor neuron involvement
- Spasticity, hyperactive deep tendon reflexes, extensor plantar response
- Muscle atrophy, diminished deep tendon reflexes, fasciculations
- Cognitive impairment
- Delayed motor milestones in infancy
- Intellectual disability
- Cognitive dysfunction typical of the cerebellar cognitive and affective syndrome (deficits in executive functioning, language, visuospatial/visuoconstructional skills)
- Skeletal involvement
- Scoliosis or kyphosis
- Pes cavus
- Arthrogryposis with distal joint contractures
Clinical syndrome, defined according to age at onset:
- Neonatal onset. Arthrogryposis multiplex congenita (AMC); neonatal hypotonia with decreased fetal movements resulting in distal joint contractures (including bilateral clubfoot, adducted thumbs, flexion contractures of fingers) followed by delayed motor milestones and progressive motor decline after the first decade [Attali et al 2009, Baumann et al 2017]
- Childhood onset. Multisystem phenotype; childhood-onset ataxia with upper and lower motor neuron dysfunction, elevation of serum CK concentration, pes cavus, other skeletal and soft tissue anomalies, intellectual disability, followed by respiratory insufficiency in adolescence [Synofzik & Schüle 2017]
- Adult onset. Cerebellar ataxia (ARCA1); cerebellar ataxia, frequent upper and/or lower motor neuron involvement, and cognitive impairment typical of the cerebellar cognitive and affective syndrome [Dupré et al 2007, Synofzik et al 2016]
Electrophysiologic Studies
Cerebellar ataxia
- Nerve conduction studies. Usually normal; may occasionally show an axonal neuropathy [Synofzik et al 2016, Yucesan et al 2017]
- Electromyography (EMG). Usually normal; may occasionally show acute or chronic neurogenic changes in individuals with clinical evidence of motor neuron dysfunction [Izumi et al 2013, Synofzik et al 2016]
AMC
- Nerve conduction studies and EMG (in newborns). May be normal [Baumann et al 2017]
- EMG (later onset). Includes mild chronic neurogenic findings [Attali et al 2009]
Brain Imaging
Brain MRI in patients with childhood-onset multisystem disease or adult-onset ataxia usually shows marked diffuse cerebellar atrophy with no other abnormalities (Figure 1).
Figure 1.
- Brain stem atrophy has been reported in one individual with childhood-onset multisystem disease [Izumi et al 2013].
- White matter abnormalities in the brain and spinal cord that mimicked findings in multiple sclerosis have been reported in two individuals with adult-onset ataxia [Algahtani et al 2017].
18F-FDG-PET imaging shows marked homogeneous hypometabolism in the cerebellar hemispheres. Pontine brain stem hypometabolism has been reported in one individual with motor neuron involvement [Synofzik et al 2016].
Establishing the Diagnosis
The diagnosis of SYNE1 deficiency is established in a proband with suggestive findings and biallelic SYNE1 pathogenic variants identified by molecular genetic testing (see Table 1).
Because the phenotype of SYNE1 deficiency is indistinguishable from many other inherited disorders with similar complex neurologic and neuromuscular phenotypes, molecular genetic testing approaches include comprehensive genomic testing or use of a multigene panel [Dupré et al 2007, Baumann et al 2017, Coutelier et al 2018, Sun et al 2019].
Note: Single-gene testing (sequence analysis of SYNE1, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.
- Comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best option. Exome sequencing is most commonly used; genome sequencing is also possible. If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
- A multigene panel that includes SYNE1 and other genes of interest (see Differential Diagnosis) may be considered to identify the genetic cause of the condition at a reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Table 1.
Gene 1 | Method | Proportion of Pathogenic Variants 2 Detectable by Method |
---|---|---|
SYNE1 | Sequence analysis 3 | ~100% 4 |
Gene-targeted deletion/duplication analysis 5 | Unknown (no data on gene-targeted del/dup analysis are available) |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Dupré et al [2007], Mademan et al [2016], Synofzik et al [2016], Baumann et al [2017], Coutelier et al [2018], Sun et al [2019]
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
Clinical Characteristics
Clinical Description
The phenotype and severity of SYNE1 deficiency vary widely and span a spectrum ranging from adult-onset cerebellar ataxia at the milder end to childhood-onset multisystem disease and prenatal-onset arthrogryposis multiplex congenita at the more severe end.
SYNE1 Adult-Onset Cerebellar Ataxia
SYNE1-deficient cerebellar ataxia, also known as autosomal recessive cerebellar ataxia 1 (ARCA1), typically begins in adulthood (mean age at onset: 31.6 years [Dupré et al 2007]; range 6 to 45 years in reported series).
The initial description of ARCA1 was that of a pure cerebellar syndrome characterized by cerebellar ataxia, dysarthria, dysmetria, and abnormalities in ocular saccades and smooth pursuit [Dupré et al 2007]. In patients from the original series, 33% had brisk reflexes and 6% had positive Babinski signs and/or ankle clonus, suggesting mild upper motor neuron involvement. Subsequently, Synofzik et al [2016] reported motor neuron dysfunction in as many as 58% of patients, comprising 31% with pure upper motor neuron dysfunction (spasticity, positive bilateral Babinski signs), 19% with combined upper and lower motor neuron dysfunction, and 8% with pure lower motor neuron dysfunction (amyotrophy, reduced reflexes, fasciculations, or neurogenic changes on EMG). Slow saccades have been reported along with other oculomotor abnormalities, including square wave jerks, ophthalmoparesis, and strabismus. Skeletal involvement with scoliosis and pes cavus is an associated finding in some patients. Reduced sense of vibration, polyneuropathy, and urge incontinence are rare occurrences [Synofzik et al 2016]. There is no evidence of muscle disease, and creatine kinase values are normal.
Individuals with SYNE1-deficient cerebellar ataxia show typical findings of the cerebellar cognitive and affective syndrome: significant deficits in attention, executive functioning, verbal working memory, and visuospatial/visuoconstructional skills [Laforce et al 2010, Mademan et al 2016].
The disease course is usually slowly progressive, resulting in a moderate degree of disability but normal life expectancy [Dupré et al 2007].
SYNE1 Childhood-Onset Multisystem Disease
A rarer phenotype is childhood-onset complex and severe multisystem disease with ataxia, upper and lower motor neuron dysfunction, pes cavus, intellectual disability, and findings suggestive of muscle disease (weakness, muscle wasting, elevated creatine kinase values, respiratory insufficiency) [Synofzik et al 2016]. Involvement of bulbar muscles may be prominent with tongue fasciculations and atrophy as well as slurred speech, and the clinical picture may mimic amyotrophic lateral sclerosis [Izumi et al 2013]. Respiratory insufficiency may present with respiratory distress or restrictive lung disease and may require noninvasive or mechanical ventilation. The reported broad range of skeletal and soft tissue abnormalities includes sacral cysts, pseudoarthrosis clavicula, hyperlaxity of joints, Achilles tendon contractures, kyphosis, scoliosis, pes cavus, cataract, and hypertelorism.
One individual had developmental abnormalities of the visceral organs (i.e., malrotation of the colon and unilateral position of both kidneys) [Mademan et al 2016, Synofzik et al 2016].
Brain MRI may show brain stem atrophy in addition to cerebellar atrophy [Izumi et al 2013].
Death between ages 36 and 44 years has been reported in a few individuals [Izumi et al 2013, Synofzik et al 2016].
SYNE1 Arthrogryposis Multiplex Congenita
SYNE1-deficient arthrogryposis multiplex congenita is characterized by decreased fetal movements in the absence of polyhydramnios, intrauterine growth restriction, or associated malformations [Attali et al 2009, Baumann et al 2017]. Neonates have severe hypotonia presenting as "floppy infant" with bilateral clubfeet, distal joint contractures with adducted thumbs and flexion contractures of fingers, and cryptorchidism in males (see Baumann et al [2017], Figure 1). Proximal weakness, facial weakness, and decreased or absent deep tendon reflexes have been reported. Motor milestones are delayed, followed by progressive motor decline after the first decade. Patients use the Gower maneuver when arising from a squatting position and have limited ability to ambulate independently and to alternate their feet when climbing stairs. Flexion contractures of the proximal interphalangeal joints of the third and fourth fingers may persist despite adequate management.
Cerebellar involvement and pyramidal signs have not been reported. Intellectual development is borderline to normal. Growth deficiency worsens with advancing age despite adequate weight gain. Hyperopia with intermittent strabismus has been reported.
Early death has been reported in two individuals: one age 22 years with severe kyphoscoliosis and restrictive lung disease who died of pneumonia and sepsis [Attali et al 2009], and an infant age four months who presented with severe neonatal hypotonia and respiratory failure. Note that the infant did not undergo genetic testing but had a sib with confirmed SYNE1 deficiency [Baumann et al 2017].
In SYNE1-deficient AMC, muscle biopsy may show variations in the size of muscle fibers without increased number of muscle fibers with central nuclei. Creatine kinase values are normal.
Genotype-Phenotype Correlations
Most pathogenic variants associated with the ARCA1 phenotype are nonsense or frameshift and are localized throughout the gene, excluding the KASH domain. Most – but not all – SYNE1 pathogenic variants associated with motor neuron involvement are located toward the 3' end of the gene [Yoshinaga et al 2017].
SYNE1 pathogenic variants associated with arthrogryposis multiplex congenita (AMC) are distal truncating variants that are expected to lead to a truncated Nesprin1α (or Nesprin1α2) isoform, which is muscle and retina specific [Duong et al 2014, Potter et al 2017].
Nomenclature
In this GeneReview, the term "SYNE1 deficiency" refers to the full neurologic and neuromuscular phenotypic spectrum of biallelic SYNE1 pathogenic variants: from autosomal recessive cerebellar ataxia 1 (ARCA1) at the mild end of the continuum to SYNE1-AMC at the most severe end of the continuum.
Note: Autosomal recessive cerebellar ataxia 1 (ARCA1) has also been referred to as "recessive ataxia of Beauce" and "spinocerebellar ataxia recessive 8" (SCAR8).
Most recently, the International Parkinson and Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement Disorders suggested the term "ATX-SYNE1" [Rossi et al 2018].
Prevalence
ARCA1, initially described in the French Canadian population, has now been reported worldwide, notably in Japan, Europe, the Middle East, and Brazil. Although its exact prevalence is not known, it is highly prevalent in the French Canadian population, which is a homogeneous founder population [Dupré et al 2007].
When Friedreich ataxia has been excluded, SYNE1 deficiency represents 5.3%-6% of unexplained early-onset (i.e., age <40 years) autosomal recessive ataxias [Mademan et al 2016, Synofzik et al 2016].
The prevalence of SYNE1-deficient arthrogryposis multiplex congenita cannot be evaluated as it has only been reported in a few families to date.
Differential Diagnosis
Table 2.
MOI | Disorder | Gene 1 | Clinical Features of Differential Diagnosis Disorder | |
---|---|---|---|---|
Overlapping w/SYNE1 Deficiency | Distinguishing from SYNE1 Deficiency | |||
AR | SCA-AR, 10 (SCAR10; ARCA3) (see Hereditary Ataxia Overview) | ANO10 |
| Seen mainly in Europe (whereas SYNE1 deficiency is seen worldwide) |
Primary coenzyme Q10 deficiency (SCAR9; ARCA2) | COQ8A | Often a pure cerebellar ataxia phenotype w/cognitive impairment & cerebellar atrophy |
| |
Friedreich ataxia | FXN |
|
| |
Boucher-Neuhäuser syndrome & PNPLA6-related Gordon Holmes syndrome (see PNPLA6-Related Disorders) | PNPLA6 |
|
| |
ARSACS (AR spastic ataxia of Charlevoix-Saguenay) | SACS |
|
| |
Spastic paraplegia 7 | SPG7 |
|
| |
AD | SCA3 | ATXN3 |
|
|
SCA6 | CACNA1A |
| Extrapyramidal features w/dystonia & blepharospasm | |
XL | Fragile X-associated tremor / ataxia syndrome (FXTAS) (see FMR1-Related Disorders) | FMR1 |
|
|
AD = autosomal dominant; AR = autosomal recessive; LMN = lower motor neuron; MOI = mode of inheritance; SCA = spinocerebellar ataxia; UMN = upper motor neuron; XL = X-linked
- 1.
Within a MOI, genes are in alphabetic order.
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs of an individual diagnosed with SYNE1 deficiency, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Table 3.
System/Concern | Evaluation | Comment |
---|---|---|
Neurologic | Assessment by neurologist for:
| • Use standardized scale to establish baseline for ataxia (SARA, ICARS, or BARS). 1, 2 • Consider electrophysiologic studies (EMG & NCS) to detect neurogenic changes or signs of neuropathy. • Brain MRI to evaluate presence & severity of cerebellar atrophy |
Refer to neuromuscular clinic (OT/PT/rehabilitation specialist). | To assess gross motor & fine motor skills, ambulation, & need for adaptive devices & PT | |
Speech | For those w/dysarthria: speech/language evaluation | |
Feeding | For those w/frequent choking or severe dysphagia, assess:
| Consider involving a gastroenterology/nutrition/feeding team. |
Respiratory | For those w/respiratory symptoms or muscular involvement: obtain pulmonary function tests | Consider involving pulmonary specialist / respiratory therapist |
Cognitive/ Psychiatric | Assess for cognitive dysfunction assoc w/cerebellar cognitive & affective syndrome (executive function, language processing, visuospatial/visuoconstructional skills, emotion regulation) | Consider use of:
|
Musculoskeletal | Assess for skeletal involvement, mainly scoliosis & pes cavus. | |
Miscellaneous/ Other | Consultation w/clinical geneticist &/or genetic counselor |
EMG = electromyogram; LMN = lower motor neuron; NCS = nerve conduction study; OT = occupational therapy; PT = physical therapy; UMN = upper motor neuron
- 1.
SARA = Scale for the Assessment and Rating of Ataxia; ICARS = International Co-operative Ataxia Rating Scale; BARS = Brief Ataxia Rating Scale
- 2.
Bürk & Sival [2018]
- 3.
Hoche et al [2018]
Table 4.
System/Concern | Evaluation | Comment |
---|---|---|
Neurologic | Assessment by neurologist of:
| Consider EMG, which may show neurogenic changes. |
Musculoskeletal | Multidisciplinary neuromuscular clinic assessment by orthopedist, physiatrist, OT/PT | To include assessment of:
|
Feeding | Assess:
| Consider involving:
|
Speech | Speech/language evaluation | |
Respiratory |
| |
Neurodevelopmental | Developmental assessment |
|
Miscellaneous/ Other | Consultation w/clinical geneticist &/or genetic counselor |
OT = occupational therapy/therapist; PT = physical therapy/therapist
- 1.
Baumann et al [2017]
Treatment of Manifestations
There is no specific treatment for SYNE1 deficiency. The goals of treatment are to maximize function and reduce complications. Each patient should be managed by a multidisciplinary team of relevant specialists such as neurologists, occupational therapists (OT), physical therapists (PT), physiatrists, orthopedists, nutritionists, speech therapists, respiratory therapists, and psychologists depending on the clinical manifestations.
Table 5.
Manifestation/Concern | Treatment | Considerations/Other |
---|---|---|